Federal Court Decision Casts Doubt on ADA Specialty Recognition Process

A recent federal court decision in Texas, AAID v. Parker, caused undue concern among AAE members that general dentists will be able to advertise as specialists. The opinion in AAID v. Parker does not in any way permit such advertising. However, it will likely have a significant impact on the ADA’s process for recognizing specialties.

Corporate Q&A: Treloar & Heisel, Inc.

Treloar & Heisel, Inc., is a longtime partner of the AAE and supporter of the endodontic specialty. As one of the AAE’s endorsed vendors, Treloar & Heisel provides members with specialized financial services and advice to guide them through every stage of their careers and into retirement. The Communiqué spoke with Ms. Amy Carbone, marketing director, to learn more about the company and its commitment to endodontists.

Dispelling Myths of Root Canals Through Education

Despite state-of-the-art advancements in endodontic treatment, Americans still fear the procedure. According to a recent AAE survey, 67 percent of Americans say fear of pain most concerns them about having root canal treatment.

The AAE hopes to dispel these fears during the 10th anniversary celebration of Root Canal Awareness Week, March 27-April 2.

Dr. Robert Amato Awarded Winkler Professorship in Endodontics

Robert B. Amato, D.M.D., has been selected as the second recipient of the Tufts University School of Dental Medicine Winkler Professorship in Endodontics. Financed through a generous bequest of the estate of Dr. Thomas F. Winkler III, the professorship honors faculty members who emulate Dr. Winkler’s leadership, service and dedication.

ACA Health Exchange Notice Requirement for Employees: FAQs

The Affordable Care Act includes an amendment to the Fair Labor Standards Act (FLSA) that requires businesses that are covered under the FLSA to inform employees about 1) the existence of the new health insurance exchanges: and 2) the health care benefits currently offered.

FAQs on HCPs

Beginning October 6, 2014, hydrocodone combination products will be reclassified as Schedule II substances and subject to tighter restrictions to help reduce diversion, misuse, and abuse of prescription painkillers. HCPs affected by the new DEA rules include Vicodin, Lorcet, Lortab and Norco.